F&O Query: Should I hold or sell Aurobindo Pharma call option?
14-07-2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
Net Sales are expected to increase by 5.1 percent Y-o-Y (up 1.3 percent Q-o-Q) to Rs. 6,555.2 crore, according to Prabhudas Lilladher.14-07-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
We enclose a press release that is being issued by the Company in connection with the USFDA approval received by APL Healthcare Limited, a wholly owned subsidiary of the Company.12-07-2023
Aurobindo Pharma arm enters into license agreement with US company; shares fall
Under the terms of the agreement, CuraTeQ has been granted exclusive license rights to commercialise BFI-751 in all major regulated markets, certain semi-regulated, and emerging markets worldwide.10-07-2023
F&O Strategy: Bull-call spread on Aurobindo Pharma
Consider a bull-call spread on Aurobindo Pharma08-07-2023
AUROBINDO PHARMA LTD. - 524804 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
This is to inform that Curateq Biologicals Private Limited, a wholly owned subsidiary of the Company has entered into an exclusive agreement with the USA based BioFactura Inc, USA to commercialise BFI-751, a proposed biosimilar to Stelara (Ustekinumab).07-07-2023
AUROBINDO PHARMA LTD. - 524804 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (DP) Regulations 201807-07-2023
Trade setup for Friday: Top 15 things to know before the opening bell
We have seen a long build-up in 80 stocks including Aurobindo Pharma, Delta Corp, GAIL India, Mahindra and Mahindra, and PVRInox, based on the open interest (OI) percentage.06-07-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform that the officials of the Company will be participating in the investor / analyst meetings on July 7, 2023.06-07-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform that the officials of the Company will be participating in the investor / analyst meeting on July 6, 2023.06-07-2023